ConductScience.org, home

Paper33517606

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact.

Yip TC and 2 others. Clin Mol Hepatol, 2021. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. Papers, record 33517606. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33517606

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact.
PubMed
Journal
Clin Mol Hepatol
PubMed
Year
2021
PubMed
Publication types
Editorial, Comment
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.5
iCite
Revised in PubMed
2021-06-18
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yip TCTerry Cheuk-Fung
2Wong GLGrace Lai-Hung
3Wong VWVincent Wai-Sun

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Hepatitis B, ChronicMajor topic
Liver NeoplasmsMajor topic
Biomarkers
Hepatitis B e Antigens
Hepatitis B virus
Humans

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on33317247Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.https://conductscience.org/library/papers/33317247

Source PubMed

Download CSV of comments and corrections

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126563120Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatol Int2016https://conductscience.org/library/papers/26563120PubMed
229353469Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend.Clin Mol Hepatol2018https://conductscience.org/library/papers/29353469PubMed
331185710KASL clinical practice guidelines for management of chronic hepatitis B.Clin Mol Hepatol2019https://conductscience.org/library/papers/31185710PubMed
433288393Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B.Eur J Intern Med2021https://conductscience.org/library/papers/33288393PubMed
527084039Adaptive immunity in HBV infection.J Hepatol2016https://conductscience.org/library/papers/27084039PubMed
631025388Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.Aliment Pharmacol Ther2019https://conductscience.org/library/papers/31025388PubMed
723415803Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.Gastroenterology2013https://conductscience.org/library/papers/23415803PubMed
832621944Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.J Hepatol2020https://conductscience.org/library/papers/32621944PubMed
924462735Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.Gastroenterology2014https://conductscience.org/library/papers/24462735PubMed
1029405329Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.Hepatology2018https://conductscience.org/library/papers/29405329PubMed
1128427875EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol2017https://conductscience.org/library/papers/28427875PubMed
1229758335Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.J Hepatol2018https://conductscience.org/library/papers/29758335PubMed
1330754963Unmet need in chronic hepatitis B management.Clin Mol Hepatol2019https://conductscience.org/library/papers/30754963PubMed
1433317247Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.Clin Mol Hepatol2021https://conductscience.org/library/papers/33317247PubMed
1529055908High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.Gut2018https://conductscience.org/library/papers/29055908PubMed
1629029102Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.J Infect Dis2017https://conductscience.org/library/papers/29029102PubMed

Download CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
41899088Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 log10 IU/mL).J Clin Med2026https://conductscience.org/library/papers/41899088PubMed
39979574Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States.Dig Dis Sci2025https://conductscience.org/library/papers/39979574PubMed
37196991Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma.Clin Mol Hepatol2023https://conductscience.org/library/papers/37196991PubMed
36603573Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase.Clin Mol Hepatol2023https://conductscience.org/library/papers/36603573PubMed
34298640Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.Cancers (Basel)2021https://conductscience.org/library/papers/34298640PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33517606

GET https://conductscience.org/api/papers/v1/33517606/authors